

## Title:

Fecal transplantation as a treatment for Clostridium difficile infection in patients with ulcerative colitis

## Authors:

Marta Izquierdo Romero, Pilar Varela Trastoy, Alejo Mancebo Mata

DOI: 10.17235/reed.2017.4941/2017 Link: <u>PubMed (Epub ahead of print)</u>

Please cite this article as:

Izquierdo Romero Marta, Varela Trastoy Pilar, Mancebo Mata Alejo. Fecal transplantation as a treatment for Clostridium difficile infection in patients with ulcerative colitis. Rev Esp Enferm Dig 2017. doi: 10.17235/reed.2017.4941/2017.



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Revista Española de Enfermedades Digestivas

CE 4941 inglés

Fecal transplantation as a treatment for Clostridium difficile infection in patients with

ulcerative colitis

Marta Izquierdo-Romero, Pilar Varela-Trastoy and Alejo Mancebo-Mata

Service of Digestive Diseases. Hospital Universitario de Cabueñes. Gijón, Spain

**Correspondence:** Marta Izquierdo Romero

e-mail: martaizquierdoromero@gmail.com

Key words: Clostridium difficile. Fecal transplantation. Inflammatory bowel disease.

Ulcerative colitis.

Dear Editor,

Clostridium difficile (CD) infection has become a critical epidemiological problem causing significant morbidity, mortality and cost (1). Patients with inflammatory bowel disease (IBD) are a high susceptibility group (2,3). Fecal transplantation (FT) is an effective and safe alternative (4) with a cure rate of up to 90% in recurrent infections.

Case report

We report the case of a 59-year-old woman with a history of ulcerative colitis (UC) diagnosed after a moderate flare of ulcerative pancolitis. She was initially treated with mesalazine and prednisone with a negative CD stool test. Due to a suboptimal response, the patient became steroid-dependent and treatment with azathioprine and infliximab (IFX) was started. The first episode of CD infection occurred two days after the first infusion of IFX. She was treated with metronidazole with a good response. Subsequently, she received a second IFX infusion. One month later, she presented with signs of CD re-infection and was treated with a second cycle of metronidazole. Afterwards, a third IFX infusion was delivered. One week later, the patient was admitted due to a third CD infection episode, despite the fact that the ulcerative colitis



(UC) was in remission. She was treated with vancomycin and metronidazole with a limited response. Thus, immunosuppressive therapy was discontinued. Given the poor progress of the patient, third line of treatment with fidaxomicin and vancomycin enemas was started. Pseudomembranous colitis persisted in the sigmoidoscopy eight days after the current treatment. Fourth line treatment with a tapering and pulse regimen of vancomycin was started and FT studies were ordered.

Finally, FT was performed 25 days after the beginning of the fourth line of treatment with an immediate clinical response. Five months later, the patient remained in clinical remission with mesalazine as a monotherapy.

## Discussion

IBD is an independent risk factor for CD infection (2). FT is an effective and safe technique for the treatment of recurrent CD infection with a high success rate (1). The eradication rate of CD in IBD seems to be similar to that seen in the general population (4,5), thus, an early use of FT is proposed.

## References

- 2. Di Bella S, Gouliouris T, Petrosillo N. Fecal microbiota transplantation (FMT) for Clostridium difficile infection: Focus on immunocompromised patients. J Infect Chemother 2015;21:230-7. DOI: 10.1016/j.jiac.2015.01.011
- Leffler D, Lamont J. Clostridium difficile infection. N Engl J Med 2015;372:1539 DOI: 10.1056/NEJMra1403772
- 4. Ramos Martínez A, Ortiz Balbuena J, Curto García I, et al. Factores de riesgo de diarrea por Clostridium difficile en pacientes con enfermedad inflamatoria intestinal. Rev Esp Enferm Dig 2015;107(1):4-9.
- 5. Ponte A, Pinho R, Mota M, et al. Initial experience with fecal microbiota transplantation in Clostridium difficile infection Transplant protocol and preliminary



results. Rev Esp Enferm Dig 2015;107(7):402-7. DOI: 10.17235/reed.2015.3767/2015

